StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Equities research analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Trading Down 0.2 %

MRNS stock opened at $0.55 on Monday. The firm’s 50-day moving average is $0.55 and its two-hundred day moving average is $0.50. The company has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.97.

Hedge Funds Weigh In On Marinus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its stake in Marinus Pharmaceuticals by 34.9% during the third quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after buying an additional 1,219,871 shares in the last quarter. Beryl Capital Management LLC bought a new stake in shares of Marinus Pharmaceuticals in the 4th quarter worth approximately $2,262,000. Woodline Partners LP boosted its holdings in Marinus Pharmaceuticals by 84.7% during the fourth quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 1,071,410 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Marinus Pharmaceuticals by 266.1% during the fourth quarter. JPMorgan Chase & Co. now owns 487,584 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 354,393 shares in the last quarter. Finally, XTX Topco Ltd increased its holdings in shares of Marinus Pharmaceuticals by 1,564.7% in the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 206,614 shares in the last quarter. 98.80% of the stock is owned by institutional investors.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.